Simultaneous administration of a low-dose mixture of donor bone marrow cells and splenocytes plus adenovirus containing the CTLA4Ig gene result in stable mixed chimerism and long-term survival of cardiac allograft in rats

Immunology

Volumn 110, Issue 2, 2003, Pages 275-286

  Jin, Yongzhu ^a   Zhang, Qingyin ^a,c   Hao, Jie ^a   Gao, Xiang ^a   Guo, Yinglu ^b   Xie, Shusheng ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN FC FRAGMENT; GENE PRODUCT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE INDUCTION; GENE TRANSFER; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RAT; RECIPIENT; SKIN ALLOGRAFT; SPLEEN CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; BONE MARROW TRANSPLANTATION; GENE THERAPY; GENETIC VECTORS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEART TRANSPLANTATION; IMMUNOCONJUGATES; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MYOCARDIUM; RATS; RATS, INBRED LEW; RATS, INBRED STRAINS; RATS, INBRED WF; SKIN TRANSPLANTATION; SPLEEN; TRANSPLANTATION CHIMERA; TRANSPLANTATION TOLERANCE;

EID: 0141992084     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01729.x     Document Type: Article

References (52)

1. Bluestone JA. Costimulation and its role in organ transplantation. Clin Transplant 1996; 10:104-9.
2. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434-8.
3. Elwood ET, Larsen CP, Cho HR et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 1998; 65:1422-8.
4. Kirk AD, Harlan DM, Armstrong NN et al. CTLA4-Ig and anti- CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94:8789-94.
5. Woodward JE, Qin L, Chavin KD et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways. Transplantation 1996; 62:1011-8.
6. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257:792-5.
7. Gainer AL, Suarez-Pinzon WL, Min WP et al. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand. Transplantation 1998; 66:194-9.
8. Kita Y, Li XK, Ohba M et al. Prolonged cardiac allograft survival in rats systemically injected adenoviral vectors containing CTLA4Ig-gene. Transplantation 1999; 68:758-66.
9. Feng S, Quickel RR, Hollister-Lock J, McLeod M, Bonner-Weir S, Mulligan RC, Weir GC. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig. Transplantation 1999; 67:1607-13.
10. Olthoff KM, Judge TA, Gelman AE, da Shen X, Hancock WW, Turka LA, Shaked A. Adenovirus-mediated gene transfer into cold-preserved liver allografts: survival pattern and unresponsiveness following transduction with CTLA4Ig. Nat Med 1998; 4: 194-200.
11. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307:168-70.
12. Slavin S, Strober S, Fuks Z, Kaplan HS. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med 1977; 146:34-48.
13. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169:493-502.
14. Nomoto K, Yung-Yun K, Omoto K, Umesue M, Murakami Y, Matsuzaki G, Nomoto K. Tolerance induction in a fully allogeneic combination using anti-T cell receptor-alpha beta monoclonal antibody, low dose irradiation, and donor bone marrow transfusion. Transplantation 1995; 59:395-401.
15. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3:783-7.
16. Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6:464-9.
17. Durham MM, Bingaman AW, Adams AB, Ha J, Waitze SY, Pearson TC, Larsen CP. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165:1-4.
18. Tsui TY, Deiwick A, Ko S, Schlitt HJ. Specific immunosuppression by postoperative infusion of allogeneic spleen cells: requirement of donor major histocompatibility complex expression and graft-versus-host reactivity. Transplantation 2000; 69:25-30.
19. Carr RI, Zhou J, Kearsey JA, Stadnyk AW, Lee TD. Prolongation of survival of primary renal allografts by feeding of donor spleen cells. Transplantation 1998; 66:976-82.
20. Westra AL, Petersen AH, Wildevuur CR, Prop J. Factors determining prolongation of rat heart allograft survival by perioperative injection of donor spleen cells. Transplantation 1991; 52: 606-10.
21. Ishido N, Matsuoka J, Matsuno T, Nakagawa K, Tanaka N. Induction of donor-specific hyporesponsiveness and prolongation of cardiac allograft survival by jejunal administration of donor splenocytes. Transplantation 1999; 68:1377-82.
22. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178:1801-6.
23. Sayegh MH, Zheng XG, Magee C, Hancock WW, Turka LA. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 1997; 64:1646-50.
24. Quesenberry PJ, Zhong S, Wang H, Stewart M. Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice. Blood 2001; 97: 557-64.
25. Storb R, Yu C, Zaucha JM et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999; 94:2523-9.
26. Hashimoto N, Narumi S, Itabashi Y, Hakamada K, Sasaki M. Efficacy of donor splenocytes mixed with bone marrow cells for induction of tolerance in sublethally irradiated mice. Transpl Immunol 2002; 10:37-41.
27. Itabashi Y, Narumi S, Hakamada K, Watanabe N, Aoki K, Sasaki M. Allogeneic chimerism established with a mixture of low dose bone marrow cells and splenocytes in sublethally irradiated mice. Transpl Immunol 2002; 10:25-30.
28. Ono K, Lindsay ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57:225-9.
29. Larregina AT, Morelli AE, Dewey RA, Castro MG, Fontana A, Lowenstein PR. FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors. Gene Ther 1998; 5:563-8.
30. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174:561-9.
31. Kiziroglu F, Miller RG. Direct effect of cyclosporin A on CD8+ T lymphocytes in a primary mixed lymphocyte reaction. Immunol Lett 1990; 24:77-86.
32. Hoffman AL, Makowka L, Cramer DV, Cai X, Banner B, Pascualone A, Hoffmann S, Starzl TE. Induction of stable chimerism and elimination of graft-versus-host disease by depletion of T lymphocytes from bone marrow using immunomagnetic beads. Surgery 1989; 106:354-63.
33. Horn TD, Bauer DJ, Vogelsang GB, Hess AD. Reappraisal of histologic features of the acute cutaneous graft-versus-host reaction based on an allogeneic rodent model. J Invest Dermatol 1994; 103:206-10.
34. Pearson TC, Alexander DZ, Hendrix R, Elwood ET, Linsley PS, Winn KJ, Larsen CP. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism. Transplantation 1996; 61:997-1004.
35. Li S, Thanikachalam M, Pang M, Kawaharada N, Aitouche A, Pham SM. A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts. Ann Thorac Surg 2001; 72:1306-10.
36. Shevach EM. Certified professionals: CD4(+) CD25(+) suppressor T cells. J Exp Med 2001; 193:F41-6.
37. Taylor PA, Lees CJ, Waldmann H, Noelle RJ, Blazar BR. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood 2001; 98:467-74.
38. Guillot C, Mathieu P, Coathalem H et al. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. J Immunol 2000; 164:5258-68.
39. Shirasugi N, Adams AB, Durham MM et al. Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002; 169:2677-84.
40. Sugiura K, Kato K, Hashimoto F et al. Induction of donor-specific T cell anergy by portal venous injection of allogeneic cells. Immunobiology 1997; 197:460-77.
41. Zhang Y, Yasumizu R, Sugiura K et al. Fate of allogeneic or syngeneic cells in intravenous or portal vein injection: possible explanation for the mechanism of tolerance induction by portal vein injection. Eur J Immunol 1994; 24:1558-65.
42. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4:403-9.
43. Jaffe HA, Danel C, Longenecker G et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992; 1:372-8.
44. Yamada A, Kishimoto K, Dong VM et al. CD28-independent costimulation of T cells in alloimmune responses. J Immunol 2001; 167:140-6.
45. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248:1349-56.
46. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177:165-73.
47. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181:1869-74.
48. Kuchroo VK, Das MP, Brown JA et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80:707-18.
49. Wekerle T, Blaha P, Langer F et al. Tolerance through bone marrow transplantation with costimulation blockade. Transpl Immunol 2002; 9:125-33.
50. Wekerle T, Sayegh MH, Hill J et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187:2037-44.
51. Wekerle T, Sayegh MH, Ito H et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation 1999; 68: 1348-55.
52. Colson YL, Zadach K, Nalesnik M, Ildstad ST. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts. Transplantation 1995; 60:971-80.